D'ALESSIO, Andrea
 Distribuzione geografica
Continente #
EU - Europa 48
AS - Asia 43
NA - Nord America 15
Totale 106
Nazione #
SG - Singapore 29
IT - Italia 20
US - Stati Uniti d'America 15
HK - Hong Kong 12
IE - Irlanda 12
NL - Olanda 6
CZ - Repubblica Ceca 3
DE - Germania 3
AT - Austria 2
IN - India 2
CH - Svizzera 1
FI - Finlandia 1
Totale 106
Città #
Singapore 14
Dublin 12
Hong Kong 12
Amsterdam 6
Boardman 5
Mezzomerico 4
Turin 4
Pardubice 3
Deiva Marina 2
Florence 2
Munich 2
New Delhi 2
Novara 2
Uzzano 2
Valduggia 2
Vienna 2
Helsinki 1
Milan 1
Trino 1
Zurich 1
Totale 80
Nome #
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 11
Cumulative radiation exposure from radiological imaging in patients with Hodgkin and diffuse large b-cell lymphoma not submitted to radiotherapy 10
. Optimisation of protection in the medical exposure of recurrent adult patients due to computed tomography procedures: development of recurrent exposures reference levels. 8
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions 8
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma 7
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 7
Reply 7
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma 7
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma 6
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study 6
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 6
Effective and organ doses in patient undergoing interventional neuroradiology procedures: A multicentre study 5
Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? 5
Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma 5
The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma 3
Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials 3
Reply 3
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 3
PETAL protocol: A phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma 3
Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study 3
Differential prognostic effect of systemic inflammation in patients with non–small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial 3
Dissecting the Tumor Microenvironment to Predict Immunotherapy Response in Hepatocellular Cancer 3
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 3
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma 3
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study 2
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 2
Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma 1
Totale 133
Categoria #
all - tutte 2.952
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.952


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024125 30 0 10 7 20 0 14 4 0 3 5 32
2024/20258 6 2 0 0 0 0 0 0 0 0 0 0
Totale 133